These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 35286896)

  • 1. Maternal serum Lamin A is a potential biomarker that can predict adverse pregnancy outcomes.
    Chen L; Xiu Y; Wu Q; Wang Y; Zhang Y; Xue J; Wang Q; Yuan Z
    EBioMedicine; 2022 Mar; 77():103932. PubMed ID: 35286896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obstetrical complications associated with abnormal maternal serum markers analytes.
    Gagnon A; Wilson RD;
    J Obstet Gynaecol Can; 2008 Oct; 30(10):918-932. PubMed ID: 19038077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Predictive value of abnormal second-trimester maternal serum triple screening markers for adverse pregnancy outcomes].
    Hu Z; Liu X; Li L; Jia C; Li D; Liu R
    Zhonghua Fu Chan Ke Za Zhi; 2014 Oct; 49(10):749-53. PubMed ID: 25537246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Significance of the maternal levels of serum alpha-fetoprotein, human chorionic gonadotropin and unconjugated estriol in various congenital developmental defects in pregnancy trimester II].
    Kostiuk EV; Zolotukhina TV; Kuznetsov MI
    Genetika; 1992 Sep; 28(9):158-62. PubMed ID: 1282117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 'Dual positivity' for neural tube defects and down syndrome at maternal serum screening: gestational outcome.
    Zanini R; Tarantini M; Cerri V; Jacobello C; Bellotti D; Lancetti S; Scalchi S; Groli C; Bianchi UA
    Fetal Diagn Ther; 1998; 13(2):106-10. PubMed ID: 9650657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromosomal abnormalities and adverse pregnancy outcome with maternal serum second trimester triple screening test for fetal Down syndrome in 4,860 Chinese women.
    Xia YP; Zhu MW; Li XT; Zhou HP; Wang J; Lv JX; Zhong N
    Beijing Da Xue Xue Bao Yi Xue Ban; 2006 Feb; 38(1):49-52. PubMed ID: 16415966
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The value of maternal first and second trimester serum data of β-hCG, PAPP-A, AFP and uE3 in the prediction of preeclampsia].
    Gu W; Lin J; Hou Y
    Zhonghua Fu Chan Ke Za Zhi; 2015 Feb; 50(2):101-7. PubMed ID: 25877605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired placental perfusion and major fetal cardiac defects.
    Fantasia I; Andrade W; Syngelaki A; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2019 Jan; 53(1):68-72. PubMed ID: 30334326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mid-trimester maternal serum AFP and hCG as markers of preterm and term adverse pregnancy outcomes.
    Tancrède S; Bujold E; Giguère Y; Renald MH; Girouard J; Forest JC
    J Obstet Gynaecol Can; 2015 Feb; 37(2):111-6. PubMed ID: 25767942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Serum marker screening during the second trimester for prenatal diagnosis and predicting pregnancy outcome].
    Yang L; Zhao L; Jiang J; Liu J; Tao H; Wang J; Wu J
    Nan Fang Yi Ke Da Xue Xue Bao; 2015 Jul; 35(7):1059-62, 1072. PubMed ID: 26198962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-trimester biochemical screening for fetal chromosome abnormalities and neural tube defects.
    Aitken DA; McCaw G; Crossley JA; Berry E; Connor JM; Spencer K; Macri JN
    Prenat Diagn; 1993 Aug; 13(8):681-9. PubMed ID: 8284287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of free beta-hCG in antenatal screening for Down's syndrome.
    Wald N; Densem J; Stone R; Cheng R
    Br J Obstet Gynaecol; 1993 Jun; 100(6):550-7. PubMed ID: 7687460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biochemical screening for chromosomal disorders and neural tube defects (NTD): is adjustment of maternal alpha-fetoprotein (AFP) still appropriate in insulin-dependent diabetes mellitus (IDDM)?
    Sancken U; Bartels I
    Prenat Diagn; 2001 May; 21(5):383-6. PubMed ID: 11360279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified multiple marker aneuploidy screening as a primary screening test for preeclampsia.
    Huang T; Bedford HM; Rashid S; Rasasakaram E; Priston M; Mak-Tam E; Gibbons C; Meschino WS; Cuckle H; Mei-Dan E
    BMC Pregnancy Childbirth; 2022 Mar; 22(1):190. PubMed ID: 35260099
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between second-trimester isolated high maternal serum maternal serum human chorionic gonadotropin levels and obstetric complications in singleton and twin pregnancies.
    Lepage N; Chitayat D; Kingdom J; Huang T
    Am J Obstet Gynecol; 2003 May; 188(5):1354-9. PubMed ID: 12748511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple marker second trimester serum screening for pre-eclampsia.
    Wald NJ; Morris JK
    J Med Screen; 2001; 8(2):65-8. PubMed ID: 11480445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Using second trimester ultrasound and maternal serum biomarker data to help detect congenital heart defects in pregnancies with positive triple-marker screening results.
    Jelliffe-Pawlowski LL; Walton-Haynes L; Currier RJ
    Am J Med Genet A; 2008 Oct; 146A(19):2455-67. PubMed ID: 18785270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome.
    Wald NJ; Cuckle HS; Densem JW; Stone RB
    Br J Obstet Gynaecol; 1992 Jan; 99(1):51-3. PubMed ID: 1372176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Second-trimester maternal serum marker screening: maternal serum alpha-fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome.
    Yaron Y; Cherry M; Kramer RL; O'Brien JE; Hallak M; Johnson MP; Evans MI
    Am J Obstet Gynecol; 1999 Oct; 181(4):968-74. PubMed ID: 10521763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for trisomy at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Bardani E; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):408-415. PubMed ID: 32621353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.